KRAS multi-inhibitor
Phase 1
Therapeutic Area: Oncology
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.
Phase 1
Therapeutic Area: Oncology
Anchored in external partnership or acquisition
This compound is under investigation, further information will be available soon.